Q1 2026 Azenta Inc Earnings Call Transcript
Key Points
- Azenta Inc (AZTA) reported strong growth in biorepositories and next-generation sequencing, reflecting sustained customer demand and solid execution.
- The company is well-positioned for a successful turnaround with a stronger organizational foundation and a sharper strategic focus.
- Azenta Inc (AZTA) has a $250 million share repurchase authorization, reflecting its commitment to delivering value to shareholders.
- The company is making meaningful progress on operational excellence initiatives, which are expected to drive margin expansion over time.
- Azenta Inc (AZTA) has a strong financial position with $571 million in cash, cash equivalents, and marketable securities, providing flexibility for strategic capital deployment.
- Organic revenue declined approximately 1% year-over-year, impacted by weak capital spending and macroeconomic uncertainties.
- Gross margin declined by 360 basis points due to underutilized lab capacity and additional costs related to rework on automated storage projects.
- The company faced higher costs in automated stores due to quality issues, which are expected to impact financials until the second quarter.
- North America experienced softer performance due to macro-driven budget constraints and temporary disruptions from a government shutdown.
- Sanger sequencing continued to decline, impacting overall performance in the multiomics segment.
Greetings and welcome to Azenta Q1 2026 financial results. (Operator Instructions) As a reminder, this conference is being recorded Wednesday, February 4, 2026.
I will now turn the conference over to Yvonne Perron, Vice President, FP&A, and Investor Relation.
Thank you, operator, and good morning to everyone on the line today. We would like to welcome you to our earnings conference call for the first quarter of fiscal year 2026. Our first-quarter earnings press release was issued before the open of the market today and is available on our Investor Relations website located at investors.azenta.com in addition to the supplementary PowerPoint slides that will be used during the prepared remarks today. Please note that effective the first fiscal quarter of 2025, the results of the Medical Systems are treated as discontinued operations.
I would like to remind everyone that during the course of the call, we will be making a number of forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
